Bo Fu1, Qingliang Chen1, Feng Zhao1, Zhigang Guo1, Nan Jiang1, Xu Wang2, Wei Wang2, Jiange Han3, Li Yang4, Yanbo Zhu5, Yanhe Ma6. 1. Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China. 2. Department of Cardiovascular Surgery, Fuwai Hospital, Beijing, China. 3. Department of Anesthesiology, Tianjin Chest Hospital, Tianjin, China. 4. Department of Cardiology, Tianjin Chest Hospital, Tianjin, China. 5. Department of Echocardiography, Tianjin Chest Hospital, Tianjin, China. 6. Department of Radiology, Tianjin Chest Hospital, Tianjin, China.
Abstract
BACKGROUND: Bicuspid aortic valve (BAV) is common congenital malformation, bicuspid aortic stenosis accounts for a substantial proportion of patients with aortic valve stenosis (AS). Bicuspid AS are more likely to have aortic dilatation with slightly less elliptical annuli, which might lead to paravalvular aortic valve regurgitation (AR) and permanent pacemaker implantation (PPM) after TAVI with higher mortality. Our study aims to understand the therapeutic efficacy and safety of transcatheter aortic valve implantation (TAVI) with a supra-annular structure-based sizing strategy in Chinese AS patients with BAV versus tricuspid aortic valve (TAV). METHODS: Seventy-four consecutive tricuspid AS patients and 44 bicuspid AS patients were included and enrolled in the study for analysis. Both groups underwent TAVI performed using balloon sizing less than mild paravalvular AR to assess the proper prosthesis size. The myocardial function within 1 year postoperative were sequentially evaluated using the New York Heart Association (NYHA) class, and echocardiography measurements. The incidence rates of complications at 30 days and 1 year were analyzed. During the 1-year follow-up, the time of death from any cause or complications in both groups was recorded. RESULTS: The study found that the percentage of patients with class III-IV of NYHA dropped after TAVI in both groups, and no significant difference between both groups at 1 year. Compared with the tricuspid AS group patients, Bicuspid group patients had more improvement in mean aortic valve gradient from baseline to 1year (-47.47±13.38 vs. -50.22±19.25 mmHg, P<0.05). There were no significant differences in 30-day and one-year compliance outcomes except a lower incidence of AR at post-procedure and 30 days in the tricuspid AS group as the Bicuspid AS group. There were no statistically significant differences in the time of death from any cause or significant complications between groups. CONCLUSIONS: TAVI has acceptable therapeutic efficacy and safety and is feasible for AS patients with BAV in China. 2020 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Bicuspid aortic valve (BAV) is common congenital malformation, bicuspid aortic stenosis accounts for a substantial proportion of patients with aortic valve stenosis (AS). Bicuspid AS are more likely to have aortic dilatation with slightly less elliptical annuli, which might lead to paravalvular aortic valve regurgitation (AR) and permanent pacemaker implantation (PPM) after TAVI with higher mortality. Our study aims to understand the therapeutic efficacy and safety of transcatheter aortic valve implantation (TAVI) with a supra-annular structure-based sizing strategy in Chinese AS patients with BAV versus tricuspid aortic valve (TAV). METHODS: Seventy-four consecutive tricuspid AS patients and 44 bicuspid AS patients were included and enrolled in the study for analysis. Both groups underwent TAVI performed using balloon sizing less than mild paravalvular AR to assess the proper prosthesis size. The myocardial function within 1 year postoperative were sequentially evaluated using the New York Heart Association (NYHA) class, and echocardiography measurements. The incidence rates of complications at 30 days and 1 year were analyzed. During the 1-year follow-up, the time of death from any cause or complications in both groups was recorded. RESULTS: The study found that the percentage of patients with class III-IV of NYHA dropped after TAVI in both groups, and no significant difference between both groups at 1 year. Compared with the tricuspid AS group patients, Bicuspid group patients had more improvement in mean aortic valve gradient from baseline to 1year (-47.47±13.38 vs. -50.22±19.25 mmHg, P<0.05). There were no significant differences in 30-day and one-year compliance outcomes except a lower incidence of AR at post-procedure and 30 days in the tricuspid AS group as the Bicuspid AS group. There were no statistically significant differences in the time of death from any cause or significant complications between groups. CONCLUSIONS: TAVI has acceptable therapeutic efficacy and safety and is feasible for AS patients with BAV in China. 2020 Annals of Translational Medicine. All rights reserved.
Authors: Polykarpos C Patsalis; Fadi Al-Rashid; Till Neumann; Björn Plicht; Heike A Hildebrandt; Daniel Wendt; Matthias Thielmann; Heinz G Jakob; Gerd Heusch; Raimund Erbel; Philipp Kahlert Journal: JACC Cardiovasc Interv Date: 2013-09 Impact factor: 11.195
Authors: Ganesh Athappan; Eshan Patvardhan; E Murat Tuzcu; Lars Georg Svensson; Pedro A Lemos; Chiara Fraccaro; Giuseppe Tarantini; Jan-Malte Sinning; Georg Nickenig; Davide Capodanno; Corrado Tamburino; Azeem Latib; Antonio Colombo; Samir R Kapadia Journal: J Am Coll Cardiol Date: 2013-04-16 Impact factor: 24.094
Authors: Michael J Reardon; David H Adams; Neal S Kleiman; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Joon Sup Lee; James B Hermiller; Stan Chetcuti; John Heiser; William Merhi; George L Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; Brijeshwar Maini; Mubashir Mumtaz; John V Conte; Jon R Resar; Vicken Aharonian; Thomas Pfeffer; Jae K Oh; Hongyan Qiao; Jeffrey J Popma Journal: J Am Coll Cardiol Date: 2015-06-05 Impact factor: 24.094
Authors: Michael J Mack; J Matthew Brennan; Ralph Brindis; John Carroll; Fred Edwards; Fred Grover; David Shahian; E Murat Tuzcu; Eric D Peterson; John S Rumsfeld; Kathleen Hewitt; Cynthia Shewan; Joan Michaels; Barb Christensen; Alexander Christian; Sean O'Brien; David Holmes Journal: JAMA Date: 2013-11-20 Impact factor: 56.272
Authors: Bo Fu; Shaopeng Zhang; Shilin Dai; Zhigang Guo; Nan Jiang; Jiange Han; Li Yang; Yanwen Shang; Yanhe Ma; Thomas Puehler; Rodrigo Bagur Journal: Ann Transl Med Date: 2021-08